We receive funding from a variety of sources that recognize the value of our high-impact research.
Steven Fliesler, PhD
Development and characterization of mouse models of RP59 DHDDS deficiency. Steven Fliesler (Co-Principal Investigator). National Eye Institute/NIH. $2,208,923. 9/1/2018-6/1/2022.
Regulation of mRNA decay in retinal development and maintenance. Xiuqian Mu (Principal Investigator). National Eye Institute. $2,024,085. 4/1/2020-3/1/2024.
Regulatory mechanisms for retinal ganglion cell genesis. Xiuqian Mu (Principal Investigator). National Institutes of Health. $1,960,167. 9/1/2017-5/1/2022.
Generation of retinal ganglion cells by direct reprograming. Xiuqian Mu (Principal Investigator). BrightFocus Foundation. $150,000. 6/1/2016-5/1/2018.
Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Sangita Patel (Co-Investigator), Michael Duffey (Co-Investigator), Mark Parker (Principal Investigator). NIH National Eye Institute. $1,972,804. 2/1/2018-1/1/2023.
NIH K08 (EY029007) Sex disparity and estradiol in Fuchs‘ endothelial corneal dystrophy. Sangita Patel (Principal Investigator). NIH. $854,900. 1/1/2018-1/1/2023.
Investigating the Action and Physiological Role of Slc4a11 in the Cornea (NIH R01 EY028580). Sangita Patel (Co-Investigator), Michael Duffey (Co-Investigator), Mark Parker (Principal Investigator). NIH. 1/1/2018-1/1/2023.